Approvals come for Regeneron and Dizal, but Roche and Replimune see knockbacks.
ApexOnco Front Page
Recent articles
The first data are dribbled out, but cross-trial comparisons look uninspiring.
Keyvibe-010 fails, but not for the reason you might have expected.
Lilly’s Mablink acquisition challenges Genmab’s move for ProfoundBio.
Tamarack data reveal vobra-duo’s toxicity, and wipe out the past six months’ share price gains.
But the group’s attempt to join Janux at the high altar of masking technology falls flat.
A tumour-agnostic label for Enhertu leads April’s US oncology approvals.
A phase 2 head and neck trial missed its primary endpoint, but the group is taking heart from survival data.